These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 23645877)

  • 1. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
    Sampat BN; Amin T
    J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indian pharmaceutical patent prosecution: The changing role of Section 3(d).
    Sampat BN; Shadlen KC
    PLoS One; 2018; 13(4):e0194714. PubMed ID: 29608604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
    Angeli F
    Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 8. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered in India--patent law 2.0.
    Kapczynski A
    N Engl J Med; 2013 Aug; 369(6):497-9. PubMed ID: 23862973
    [No Abstract]   [Full Text] [Related]  

  • 11. Intellectual property. Challenges to India's pharmaceutical patent laws.
    Sampat BN; Shadlen KC; Amin TM
    Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
    [No Abstract]   [Full Text] [Related]  

  • 12. Campaigners urge India to resist pressure to change patent laws.
    Kmietowicz Z
    BMJ; 2015 Jun; 350():h3218. PubMed ID: 26066656
    [No Abstract]   [Full Text] [Related]  

  • 13. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
    Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patent dispute: Delhi High Court gives a boost to access to affordable medicines.
    Menghaney L
    Indian J Med Ethics; 2010; 7(2):97-100. PubMed ID: 20432882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. India: New patent law may restrict access to HIV/AIDS treatments.
    Cruess G
    HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Glivec® case: the first example of a global debate on the drug patent system].
    Moital I; Bosch F; Farré M; Maddaleno M; Baños JE
    Gac Sanit; 2014; 28(6):470-4. PubMed ID: 25110309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.